Form 4: Capricor Therapeutics Director Exercises Stock Options
SEC Form 4 Filing
Director George W. Dunbar Jr. exercised stock options to acquire 750 shares of Capricor Therapeutics at $1.39 per share.
Summary
- On March 3, 2025, George W. Dunbar Jr., a director of Capricor Therapeutics, exercised stock options.
- This transaction involved the acquisition of 750 shares of common stock at a price of $1.39 per share.
- Following the transaction, Dunbar directly owns 11,306 shares of Capricor Therapeutics.
- The stock options were granted on March 3, 2015, and were fully vested and exercisable as of that date.
- The exercise price and number of shares were adjusted to reflect a 1-for-10 reverse stock split on June 4, 2019, and a share reprice on February 12, 2020.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, reflecting a standard transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be informative for investors.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 03/03/2015 | Stock options granted to George W. Dunbar Jr. |
| 03/03/2015 | Shares were fully vested and exercisable as of this date. |
| 06/04/2019 | 1-for-10 reverse stock split occurred. |
| 02/12/2020 | Share reprice to $1.39 per share occurred. |
| 03/03/2025 | Director exercised stock options. |
| 03/04/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.